Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Hydration is an important part of preventing and treating sickle cell crises, writes columnist Oluwatosin Adesoye, who shares ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Understanding Sickle Cell Anemia and the Need for Early DiagnosisSickle cell anemia is a genetic blood disorder caused by a ...

High bilirubin levels increase the risk of developing bilirubin gallstones—a type of gallstone more prevalent in Sickle Cell ...

In this article, we explore the experiences of sickle cell patients in emergency care and the ways they can advocate for themselves ...

New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.

Accurate pain reporting in sickle cell disease is critical to effective pain assessment and management, but accuracy depends on patient comprehension of forms.

Newborn screening: Many countries routinely screen newborns for sickle cell disease as part of standard health checks. Pain management: Over-the-counter pain relievers or prescription medications ...

Sickle cell disease causes blood cells to become crescent-shaped, restricting blood flow and leading to severe pain that may require hospitalization. It can reduce life expectancy by 20 to 30 years.